September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Long Term Risk for Geographic Atrophy in Correlation to Choroidal Thickness in Patients Receiving a Treat-and-Extend Regimen of Anti-Vascular Endothelial Growth Factor Agents
Author Affiliations & Notes
  • Elona Gavazi
    Ophthalmology, Columbia University, NY, New York, United States
    VRMNY, New York, New York, United States
  • Lekha Ravindraraj
    VRMNY, New York, New York, United States
  • Nicolas Alessandro Yannuzzi
    VRMNY, New York, New York, United States
  • Samir N Patel
    VRMNY, New York, New York, United States
  • Luna Xu
    VRMNY, New York, New York, United States
  • K Bailey Freund
    VRMNY, New York, New York, United States
  • Footnotes
    Commercial Relationships   Elona Gavazi, None; Lekha Ravindraraj, None; Nicolas Yannuzzi, None; Samir Patel, None; Luna Xu, None; K Bailey Freund, Bayer HealthCare (C), Genentech (C), Heidelberg Engineering (C), Ohr Pharmaceutical (C), ThromboGenics (C)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science September 2016, Vol.57, No Pagination Specified. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Elona Gavazi, Lekha Ravindraraj, Nicolas Alessandro Yannuzzi, Samir N Patel, Luna Xu, K Bailey Freund; Long Term Risk for Geographic Atrophy in Correlation to Choroidal Thickness in Patients Receiving a Treat-and-Extend Regimen of Anti-Vascular Endothelial Growth Factor Agents. Invest. Ophthalmol. Vis. Sci. 201657(12):.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To analyze the long-term risk of geographic atrophy (GA) development in correlation to choroidal thickness in a consecutive series of patients with treatment-naïve neovascular age-related macular degeneration (n-AMD) on a treat-and-extend regimen (TER) of intravitreal injections of anti-vascular endothelial growth factor (anti-VEGF) agents.

Methods : Central choroidal thickness (CCT) was retrospectively measured using spectral-domain optical coherence tomography (SD-OCT) at baseline and last follow-up in a cohort of consecutive, treatment-naïve, n-AMD patients that displayed GA formation during their TER of anti-VEGF agents. Neovascular lesion subtyping adhered to the anatomical classification system utilizing fluorescein angiography and SD-OCT, as types 1 (sub-retinal pigment epithelium), 2 (subretinal), 3 (intraretinal), or mixed neovascularization.

Results : Eighty-six eyes of 86 patients, 24 men (28%) and 62 women (72%) were included in final analysis. They were followed for an average of 57.2 months (median 59.3, range 24.4 - 78.7) and received in average 32.8 injections (median 32.1, mean injection/month 0.62). The mean, square rooted baseline and final area of GA were respectively 0.294 mm2 and 2.443 mm2. The mean baseline and final CCT were respectively163 and 149 micron. The likelihood of GA formation was analyzed in correlation with CCT, neovascularization subtype, number of injections and other variables in univariate and multivariate analyses.

Conclusions : Baseline CCT does not appear to be a significant independent predictor for the long-term risk of GA development in treatment-naive n-AMD eyes on a TER of anti-VEGF agents. Final CCT is a statistically significant predictor (R2 = 0.48) but the weak slope denotes marginal clinical importance. The total number of injections in multivariate analysis is not a significant predictor to the risk of GA formation. The presence of type 1 neovascular lesions remains the strongest predictor that correlates to a decrease in the risk of GA formation in uni- and multivariate analysis (p < 0.0001).

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×